HomeNewsBusinessMoneycontrol ResearchSyngene: Preferred CRAMS play for the long term

Syngene: Preferred CRAMS play for the long term

The company’s underperformance, compared to the Nifty, is not justified, and there is merit in considering the stock at the current levels. In the medium term, complex APIs and biologics manufacturing would be the growth drivers.

Anubhav Sahu

January 03, 2024 / 09:44 IST

Syngene: Preferred CRAMS play for the long term

Recent consolidation provides an opportunity to accumulate stock

Watch Webinar

PRO Panorama

Moneycontrol Pro Panorama | How to be long term greedy

Sep 5, 2025 / 03:14 PM IST

For September 5 edition of Moneycontrol Pro Panorama: Flood-hit Punjab spells bad news for food security, caution for borrowers as...
Read Now
PRO Weekender

Moneycontrol Pro Weekender | GST in Gloriously Silly Terms

Sep 6, 2025 / 10:00 AM IST

GST saw a Glorious Structural Turnaround this week and many other acronyms
Read Now

Unlock This Article

Are you a PRO subscriber? Sign In

What Do You Get

Ad free Experience

Seamless navigation, faster responses.
Expert Perspective

Explore 230+ exclusive editorials every month
+

Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights

40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events

Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters

Stay ahead with daily and weekly insights

View Offers

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More